DalarginДаларгин
A synthetic opioid hexapeptide, Tyr–D-Ala–Gly–Phe–Leu–Arg, derived from the naturally occurring peptide Leu-enkephalin. Studies have examined its effects in perioperative care and tissue-injury models.
What the studies found
Comparison in people · 2025
Surgery comparison reported metabolic and complication improvements
- Stress-hormone response and metabolism
- Lower stress-hormone release and more favorable aerobic-metabolism measures reported with the combined protocolDalargin plus carbohydrate loading versus standard perioperative care; numerical changes not available in the abstractPerioperative assessments
- Postoperative complications
- Fewer complications reported; counts, types and effect uncertainty not extractedNo numerical risk reduction inferred
The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.
Study notes · methods, sources and limitations
Participants or model 58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients
Design 58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients
- Study groups
- 29 combined-intervention versus 29 standard-care patients; 58 total
Important limitations
- Dalargin was combined with carbohydrate loading. The abstract does not quantify outcome differences or isolate Dalargin.
- Dalargin was combined with carbohydrate loading; the independent contribution of each is unresolved. Randomization, masking and allocation concealment were not established in the abstract. Numerical complication counts, effect sizes and uncertainty require the original outcome tables. Perioperative metabolic findings do not demonstrate improved tumor control or cancer survival.
- A combined perioperative intervention, not isolated Dalargin efficacy or an anticancer trial. Reported differences remain qualitative until outcome tables can be checked.
Siberian Journal of Oncology. 2025;24(1):29–38 · Original clinical journal publication
Animal research · 2026
Cardiac injury marker was 27% lower in stressed rats
- Cardiac injury marker CK-MB
- 27% lower with Dalargin than stressed controlsAnimal biomarker comparison, not a clinical event reduction24-hour stress modelNo p-value or confidence interval supplied in the abstract
- Pump-function response to Dalargin
- Partial reversal reported; numerical treated-versus-stress functional estimates not provided
- Stress model changes, not Dalargin effects
- End-systolic volume doubled and left-ventricular ejection fraction fell 27%Stress versus unstressed baseline/control; these figures must not be presented as treatment improvements
In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.
Study notes · methods, sources and limitations
Participants or model Female Wistar rats exposed to 24-hour immobilization
Design Female Wistar rats under 24-hour immobilization stress; Dalargin versus stressed controls. Group sizes, precision estimates and p-values not supplied by the publisher abstract.
- Reported animal protocol
- 0.125 mg/kg intraperitoneally, before and twice during the stress periodExperimental regimen; not clinical administration advice
Important limitations
- An animal experiment; functional recovery was only described qualitatively and human benefit was not tested.
- Animal stress model; this does not establish cardioprotection in people. Sample size, masking and full statistical methods require the complete paper.
- Preclinical stress-injury model. No evidence here for human stress cardiomyopathy treatment or reduced cardiovascular events.
Bulletin of Experimental Biology and Medicine. 2026;182(8):129–133. · Indexed abstract
Animal research · 2021
2021 bone study: GHK plus Dalargin improved neutrophil measures
Study of multiple preparations
- Phagocytic index: GHK plus Dalargin
- 71.3 ± 5.1% versus 30.8 ± 3.1% in fracture controlsUninjured control 70.7 ± 7.0%; n=8/group; M±m as printedDay 10p<0.05 versus fracture control; Table 1 marks *2
- Phagocytosis activation index: GHK plus Dalargin
- 2.4 ± 0.3 versus 0.4 ± 0.03 in fracture controlsUninjured control 2.7 ± 0.2; GHK alone 1.2 ± 0.1; Dalargin alone 1.3 ± 0.1Day 10p<0.05 versus fracture control; pairwise superiority to single peptides not established by table symbols
- Oxygen-dependent reserve: GHK alone
- No significant increase versus fracture controls; remained below the uninjured referenceFigure 5 group 2 has no fracture-control significance star; no exact bar values digitizedDay 10Figure marker indicates p<0.05 versus uninjured animals
At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.
More reported outcomes
- Oxygen-dependent reserve: GHK plus Dalargin
- Increased versus fracture controls; not marked different from the uninjured referenceFigure 5 group 5; this does not establish equivalence to healthy animalsDay 10p<0.05 versus fracture control; exact plotted values not extracted
- GHK plus Thymogen: phagocytic index
- 75.3 ± 5.9% versus 30.8 ± 3.1% in fracture controlsThis combination also improved uptake; its oxygen-dependent reserve did not show the same restoration pattern as GHK plus DalarginDay 10p<0.05 versus fracture control; Table 1
- Bone repair
- More advanced callus remodeling described with GHK combinations; fracture line described as barely visibleQualitative histology/radiography, not a quantified union-time or strength endpointDay 10
- Safety and clinical outcomes
- No formal adverse-event series, infection-rate reduction or human treatment outcome reported
Study notes · methods, sources and limitations
Participants or model Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified
Design Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified. Eight displayed groups: uninjured saline, fractured saline, three single peptides and three pairwise combinations. Assessments at day 10; local intraosseous exposure.
- Assay group sizes
- Table 1 and Figure 5 report n=8/group; histology sample flow not separately established
Important limitations
- Eight rats per assay group; local experimental delivery. GHK alone did not significantly improve oxygen-dependent reserve. Bone-repair findings are qualitative.
- Small animal groups; randomization, blinded assessment, power calculation and complete participant flow are not described. The numerical endpoints are neutrophil assays, not fracture-union time, mechanical bone strength or clinical infection rates. Table significance symbols compare uninjured or fracture controls; they do not establish equivalence to healthy animals or a formal combination-interaction effect. Local intraosseous administration differs from the systemic 2011 patent experiment. Shared authors and related models do not establish independent replication; cohort overlap is unresolved. The peptide tested was unbound GHK, not GHK-Cu. Pairwise combinations used two peptides per group. The study had no three-peptide cocktail.
- This is an original animal study, not a clinical review. Neutrophil uptake and oxygen-dependent reserve are surrogate assays; bone outcomes are descriptive. The claimed synergy lacks a formal interaction test. The 2021 local-delivery study and the 2011 systemic patent belong to a related research program; independent replication or shared animals cannot be established from the available reports.
Humans and their Health / Chelovek i ego zdorovye. 2021;24(4):59–67 · Original preclinical journal study; not a literature review
About Dalargin
Names in this research collection
Dalargine · Tyr–D-Ala–Gly–Phe–Leu–Arg
Identity / background source ↗
Research background
A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.
Pregnancy and offspring research
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Postnatal animal treatment, not maternal administration or human neonatal efficacy.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
Shustov papers, coauthors and archival leads ↗
More study findings
Completed trial · registry only · 2020
Registered Dalargin and Leitragin COVID-19 trial
The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.
Study notes · methods, sources and limitations
Participants or model 320 actual enrollees reported. The four arm descriptions list 80 participants apiece.
Design Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.
- Actual enrollment
- 320 participants
Important limitations
- Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.
ClinicalTrials.gov NCT04346693. · Trial registry
Animal research · 2014
Twenty-one-day loaded swimming comparison
Study of multiple preparations
- Dalargin · first swim
- 79.7±5.4 → 218.0±6.6 sDay 0 to 21. Second and third day-21 swims: 187.3±5.4 and 181.6±6.7 s.
- Control · first swim
- 63.8 → 71.9±3.9 sDay 0 to 21. Control rose to 91.4±3.3 s on day 28.
Cortexin and Dalargin were given to separate rat arms.
Study notes · methods, sources and limitations
Participants or model Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.
Design Repeated forced swimming with a 7%-body-mass load. Three swims per test session measured persistence and recovery. Tests before treatment, on days 7, 14 and 21, and one week after dosing.
Important limitations
- Baseline swimming means differed.
- Unequal baseline results, non-equivalent doses and repeated training exposure limit between-group interpretation.
- The arms compare the peptides individually. They do not test a Cortexin–Dalargin combination.
Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9
Comparison in people · 1998
1998 ulcer study: immune changes reported; pairing unresolved
Study of multiple preparations
- T-cell immune measurements
- Improvement toward healthy-reference levels reported; no numerical treatment effect or arm-specific denominator suppliedE-rosette and theophylline-sensitive/resistant assays; healthy donors are reference controls, not an untreated ulcer-treatment arm
- Unchanged index and source inconsistency
- The abstract says TFS-RFC did not differ from controls before or after treatmentThe same abstract uses inconsistent TPP/TPS/TFP/TFS abbreviations and also lists reduced indices; exact subset interpretation requires the original paper
- Clinical healing and safety
- No ulcer-closure rate, relapse rate, adverse-event count or combination-specific clinical endpoint in the abstract
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
Study notes · methods, sources and limitations
Participants or model 120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
Design 120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
- Clinical cohort
- 120 ulcer patients and 30 healthy donorsThese totals do not establish randomization, treatment-group sizes or simultaneous dual treatment
- Dose, route and schedule
- Not supplied in the abstract
Important limitations
- 120 ulcer patients and 30 healthy-reference donors. Treatment arms, simultaneous use, doses and clinical healing outcomes are unavailable; one subset measure was unchanged.
- Original treatment-arm table, doses, routes, concurrent care, allocation and follow-up not recovered. Historical rosette subpopulations must not be relabeled as modern flow-cytometry CD4/CD8 or regulatory T-cell measurements. Healthy donor references do not control for other ulcer treatments. The abstract does not prove simultaneous coadministration, additive benefit or synergy.
- This is the direct human research lead, with unresolved exposure assignment. It is not a verified combination trial or a validated healing regimen. The neutral sentence and inconsistent abbreviations remain visible.
Lik Sprava. 1998;(3):56-58. PMID 9695565 · Original journal publication
Animal research · 1995
Rat ulcer comparison ranked three separate peptide preparations
Study of multiple preparations
- Relative protective activity
- Mucosalin > Dalargin > Thymalin, as ranked in the abstractQualitative ranking; no effect size, uncertainty or pairwise significance provided
- Combination exposure
- No simultaneous Thymalin plus Dalargin administration established by the abstract
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
Study notes · methods, sources and limitations
Participants or model 80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
Design 80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
- Animal program
- 80 male Wistar rats in totalNot 80 rats per peptide and not a human cohort
Important limitations
- Dose, route, duration, individual arm sizes and lesion-score tables are unavailable in the abstract. Mucosalin is a separate experimental extract; its result is not transferred to either Thymalin or Dalargin. Comparative animal protection is not evidence of synergy or human ulcer healing.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Lik Sprava. 1995;(1-2):53-55. PMID 7483545 · Original journal publication
Animal research · 1987
Wound blood flow increased; unaffected-tissue flow was unchanged
- Wound microcirculation
- Increased granulation-tissue blood flow, new capillary formation and lower vascular resistance describedMicrosphere method; no numerical flow values or effect uncertainty in the abstract
- Unaffected tissue
- No effect on capillary blood flow reportedNeutral tissue-specific finding
- Preparation boundary
- The tested preparation was a collagen–Dalargin complexNo Thymalin co-treatment or general formulation equivalence established
A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.
Study notes · methods, sources and limitations
Participants or model Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
Design Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
Important limitations
- Original carrier controls, dose, route, sample sizes and numerical hemodynamic tables require full text. A local wound-flow finding is not a general increase in systemic circulation or proof of clinical healing.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Biull Eksp Biol Med. 1987;104(12):651-654. PMID 2446676 · Original journal publication
Animal research · 1988
Rat wounds: threefold fibroblast mitotic-index increase
- Fibroblast proliferation
- 3-fold increase in mitotic index reportedRat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable
- Repair outcomes
- Capillary growth, granulation/scar maturation and epithelialization described as fasterNo verified numerical days-to-closure estimate; threefold mitosis is not threefold faster healing
- Safety
- No adverse-event counts or long-term scarring outcomes supplied
The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.
Study notes · methods, sources and limitations
Participants or model Rat skin wounds; group sizes and observation times absent from the abstract.
Design Rat skin wounds; group sizes and observation times absent from the abstract.
- Reported routes
- Intraperitoneal injection and local applicationDose, frequency and duration not supplied by the abstract
Important limitations
- Dalargin alone, via injection or local application. The abstract does not quantify days to healing, dose or group sizes; no Thymalin synergy was tested.
- No dose, denominator, exact observation schedule or numerical healing-time table in the abstract. Separate single-agent animal research; it does not establish Thymalin–Dalargin synergy or human wound benefits.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Biull Eksp Biol Med. 1988;106(10):487-490. PMID 3191245 · Original journal publication
Lab research · 1987
Dalargin inhibited stimulated human lymphocyte proliferation
- Mitogen-induced proliferation
- Inhibited by Dalargin at 10⁻¹²–10⁻⁷ MHuman-cell assay; no numerical inhibition percentage or donor count supplied
- Naloxone contrast
- Blocked the reported Dalargin-associated inhibitionAssay-specific pharmacology, not proof of a beneficial immune effect in people
Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.
Study notes · methods, sources and limitations
Participants or model Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
Design Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
- Experimental concentration
- Dalargin 10⁻¹²–10⁻⁷ M; naloxone range 10⁻⁸–10⁻⁶ MCulture concentrations, not human doses; timing unavailable
Important limitations
- No donor count, numerical response curve or effect uncertainty in the abstract. Opioid ligands and mitogen conditions differ; no Thymalin combination or human immune outcome was tested.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Farmakol Toksikol. 1987;50(3):58-59. PMID 3038604 · Original journal publication
Lab research · 1987
Dalargin’s immune effects changed with initial cell responsiveness
- Lymphocyte proliferation
- Increase or decrease depended on baseline responsiveness to phytohemagglutininBidirectional culture response; not a uniform immune stimulant
- Leukocyte migration
- Inhibition reported with Dalargin 0.1 µg/mLCulture assay; numerical migration change unavailable
Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.
Study notes · methods, sources and limitations
Participants or model Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
Design Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
- Serum correlation component
- Serum from 55 patients; endogenous leu-enkephalin inversely correlated with mitogen responsivenessObservational association, not 55 patients receiving Dalargin
Important limitations
- In-vitro donor counts, response magnitudes and exposure duration unavailable in the abstract. Observational serum results and drug-exposure experiments are different components.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128 · Original journal publication
Lab research · 1988
NK-cell contacts and activity increased in a human-cell assay
- NK-cell function
- More effector–target contacts and active NK cells describedK-562 laboratory target assay; no clinical cancer outcome or numerical benefit estimate
- Naloxone finding
- At 10⁻⁶ M, naloxone itself enhanced target contacts and lytic activity in this assayDifferent response from the 1987 proliferation-blockade experiment; receptor effects are assay-dependent
Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.
Study notes · methods, sources and limitations
Participants or model Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
Design Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
- Experimental exposure
- Dalargin preincubation at 10⁻¹⁴–10⁻⁸ MDuration unavailable; the later peak-range sentence has a malformed exponent and is not reconstructed
Important limitations
- Original response curves, donor counts and route-independent safety require full text. One activity-peak exponent is malformed in the indexed abstract; no corrected range is asserted. Natural cytotoxicity in vitro is not anticancer efficacy.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025 · Original journal publication
Lab research · 1994
Timing-sensitive opioid effects in lymphocyte cultures
- Timing-dependent culture response
- Largest opioid-class stimulation described after addition at 24–48 hoursClass-level statement under suboptimal antigen conditions; not a Dalargin-specific human schedule
- Ligand differences
- Selective mu- and delta-ligands had effects in different directionsDAGO and DADLE findings are not assigned to Dalargin
- Dalargin-specific quantitative gap
- No separate numerical Dalargin effect or concentration table provided
The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.
Study notes · methods, sources and limitations
Participants or model Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Design Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Important limitations
- Concentrations, denominators, uncertainty and precise ligand-specific contrasts require the full paper. Culture timing is not a clinical administration schedule and does not establish Thymalin combination benefit.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868 · Original journal publication
Lab research · 1994
NK-cell cytolysis increased in a separate laboratory report
- NK-cell cytolysis
- Increase described with Dalargin and endogenous peptidesCell-culture endpoint, not a clinical antitumor response
- Numerical extraction gap
- No concentration, effect magnitude, denominator or uncertainty in the abstract
Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.
Study notes · methods, sources and limitations
Participants or model Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
Design Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
Important limitations
- The concentration in the 1988 human-cell assay applies only to that experiment. No Thymalin combination, human treatment or cancer-survival benefit established.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Eksp Klin Farmakol. 1994;57(1):55-57. PMID 8142867 · Original journal publication
Comparison in people · 1991
Mucosal DNA-synthesis marker increased during a 20-day comparison
- Mucosal DNA-synthesis marker
- Significant increase in labelled epithelial nuclei described after DalarginFundal and duodenal-bulb biopsies; exact indices, p-value and group sizes unavailable20 days
- Clinical endpoint gap
- No numerical ulcer-closure, relapse, symptom or safety comparison in the abstract
After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.
Study notes · methods, sources and limitations
Participants or model Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
Design Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
Important limitations
- Historical active comparator; allocation, masking and other ulcer care require full text. A proliferation marker is not a demonstrated clinical healing or combination-treatment benefit.
- Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344 · Original journal publication
Animal research · 2007
Dalargin’s mucin effects differed by tissue compartment and timing
- Villus mucin-production index
- Reported baseline 60.56±4.01; 110.2±0.75 at day 3 with DalarginHistochemical index, source-specific units; not an 82% clinical healing benefit. Original uncertainty type not defined.
- Separate untreated-ulcer reference
- 57.7±0.95 reported for villus mucin production without DalarginConclusion gives this reference separately; no matched-time treatment effect or confidence interval inferred
- Crypt mucin response in ulcer conditions
- No response to Dalargin over the first three days describedNeutral location-specific finding, despite the favorable villus narrative
The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.
More reported outcomes
- Intact-mucosa early crypt coefficient
- 2.19±0.07 in controls versus 1.85±0.1 after DalarginNeutral-mucin cytochemical coefficient; an early decrease, not uniform stimulationDay 1p<0.01
- Trefoil-peptide signal
- Early fall after Dalargin in ulcer-bearing animals, followed by return toward initial levels on days 2–3Qualitative histochemistry; no clinical consequence established
Study notes · methods, sources and limitations
Participants or model Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
Design Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
Important limitations
- No animal group sizes, masking or complete statistical plan supplied. Histochemical indices are surrogate tissue measures, not clinical ulcer-healing percentages. The source gives both a general baseline and an untreated-ulcer reference; they are not interchangeable control time points. Intact and ulcer-bearing animals show different time courses. Dose is explicitly printed for the intact group but not repeated for the ulcer group.
- This paper extends the mucosal-repair hypothesis while showing phase- and compartment-dependent responses. It is not a Thymalin combination experiment or a quantified clinical healing trial.
Uspekhi sovremennogo estestvoznaniia. 2007;(12, part 1):33–36. · Original animal journal publication
Animal research · 2016
Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides
- Dalargin
- Reported normalization of gravimetric, proliferation and hepatocyte nucleolar measures
- Non-opioid analogue: incomplete effect
- Gravimetric and nucleolar parameters not normalized; proliferating-cell pool increasedRelated analogue is not Dalargin
- Redox outcomes
- Both preparations reduced free-radical oxidation and improved antioxidant defenses; numerical effects unavailable
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Study notes · methods, sources and limitations
Participants or model Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract
Design Dalargin or a non-opiate Leu-enkephalin analogue, 100 µg/kg on postnatal days 2–6; day-7 liver growth, proliferation, nucleolar and redox assays.
Important limitations
- Postnatal animal treatment, not maternal administration or human neonatal efficacy.
- Postnatal animal treatment, not maternal administration or human neonatal efficacy. Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function. The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.
Bulletin of experimental biology and medicine. 2016;162(2):203. PMID 27909965 · Original journal publication
Animal research · 2020
Dalargin in the 2020 peptide-profile study
Findings for Dalargin within a multi-preparation animal study
- Dalargin: hypoxia time
- 170±8 s versus displayed control 95±3 sTable 2, M±m; male rats; ten per group
- Dalargin: loaded swimming
- 201±12 s versus displayed control 135±6 sTable 2, M±m; female rats; ten per group; 10% body-weight load
Hypoxia and swimming results came from separate animal cohorts. The original raw times and dose statements are retained below.
Study notes · methods, sources and limitations
Participants or model Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.
Design Ten rats per group; males for chamber hypoxia (time to agonal signs) and females for loaded swimming (time to exhaustion). Single rectal exposure one hour before testing; saline vehicle controls. Separately performed experiments were standardized and pooled.
- Reported animal exposure
- Dalargin 0.56 mg/kg rectally, once, one hour before testingExperimental route; not a human regimen
Important limitations
- Different experiments and unequal doses limit comparisons. The 2019 book reproduces these results; it is not independent confirmation. The paper gives no pairwise p-value showing superiority for this preparation.
- Different-sex cohorts and separate experiments contributed to the two endpoints; randomization is stated, but masking, allocation concealment and complete animal flow are not established. Doses were unequal, and the nominal experimental-preparation dose in methods conflicts with the discussion maximum. Table 2 does not resolve each complex’s actual exposure. Table 2 reports M±m; its uncertainty notation is retained without relabeling it as a verified SD. No preparation-specific pairwise p-values or confidence intervals establish PPK-V superiority over Cortexin. T-scores standardize results against experiment-specific controls. Their percentages and ratios cannot be interpreted as proportional increases in raw swim time or clinical performance. Table 1’s final bin is printed >1 kDa, while the narrative describes <1 kDa. Some fractions do not sum to 100%; blank cells are not assumed zero and values are not renormalized. The 5–10 kDa association is observational within the pooled analysis, not isolation of an active sequence or proof of brain penetration. Rectal results do not establish intranasal delivery. Matching 2019 and 2020 numerical tables are treated as one research program. No human PPK-V efficacy or long-term safety follows from these results.
- This is a composition–activity hypothesis from pooled animal experiments. PPK-V is a distinct experimental cortex hydrolysate, not Cortexin or the brainstem PPK-B. Unequal exposures, source inconsistencies and matching earlier tables limit comparisons. No clinical superiority, formal combination synergy or intranasal PPK-V delivery has been established.
Search for the optimal mass profile of neuropeptides for the implementation of antihypoxic and activating actions. Pharmacy Formulas. 2020;2(4):72–81. · Original animal and analytical journal research
Animal research · 2014
GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results
Study of multiple preparations
- Neutrophil phagocytic index
- 69.17 ± 3.70% with GHK + Dalargin and 72.17 ± 5.25% with GHK + Thymogen versus 31.67 ± 2.03% with fracture plus saline.Day 10Both p<0.05 versus fracture plus saline
- Phagocytic index with GHK alone
- 41.80 ± 2.50% with GHK, versus 31.67 ± 2.03% with fracture plus saline and 67.01 ± 4.33% without fracture.Table 1 marks p<0.05 versus both controls
- Fracture radiographs
- The authors describe a less visible fracture line in treated groups, particularly with combinations.Descriptive assessment
After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.
Study notes · methods, sources and limitations
Participants or model Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.
Design The researchers fixed a closed right femoral fracture with an intramedullary wire. After ten days they measured neutrophil uptake of latex particles, counting 100 cells per smear.
Important limitations
- The 2021 Mal conference paper repeats treatment-group phagocytosis means and errors exactly. The two reports are treated as overlapping evidence. The separate 2021 journal paper used intraosseous delivery and reports different numbers. The paper describes radiographs qualitatively. The cellular assays do not establish fracture union, mechanical bone strength or clinical effects.
Innovations in Medicine, Kursk State Medical University conference proceedings. 2014; pp. 256–258. · Conference proceedings paper
Animal research · 2021
GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report
Study of multiple preparations
- Stimulated NBT response in blood neutrophils
- 2.9× with GHK + Dalargin, 1.75× with GHK + Thymogen and 1.74× with Thymogen + Dalargin.Reported fold changes versus fracture control
- Neutrophil functional reserve
- 1.69× with GHK + Dalargin, 1.31× with GHK + Thymogen and 1.28× with Thymogen + Dalargin.Versus fracture control. GHK + Dalargin approached the uninjured reference.Day 10
- Oxygen-dependent measures with GHK alone
- The authors reported no substantial effect.Figure 1 and results text
GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.
More reported outcomes
- Latex uptake
- The GHK + Dalargin and GHK + Thymogen phagocytic indices were 69.17 ± 3.70% and 72.17 ± 5.25%, matching the 2014 results.
Study notes · methods, sources and limitations
Participants or model The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.
Design At day 10 the investigators assessed neutrophil oxidative activity using spontaneous and stimulated nitroblue tetrazolium (NBT) reduction. Functional reserve was the ratio of stimulated to spontaneous NBT. They also measured uptake of latex particles.
Important limitations
- The published phagocytosis values repeat the 2014 report. The 60 animals stated in the 2021 methods are treated as overlapping with the earlier report. The 2021 intraosseous journal paper is a separate source with different methods and results. A normal-range laboratory result alone cannot establish equivalence to uninjured animals. These experiments do not establish a combined clinical effect or reduced infection rates.
Belikov Readings, 9th International Scientific and Practical Conference proceedings. Pyatigorsk, 2021; pp. 230–237. · Conference proceedings paper
Comparison in people · 2023
Dalargin and oxidative stress in severe combined trauma: a prospective clinical study
- Mortality
- 8/38 (21.1%) versus 17/66 (25.8%)p=0.6412; nonsignificant
- ARDS
- 2/38 (5.3%) versus 14/66 (21.2%)p=0.0457
- Acute kidney injury
- 1/38 (2.6%) versus 13/66 (19.7%)p=0.0286
Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.
More reported outcomes
- Overall ICU stay
- 12.5 [6.0–34.5] versus 15.0 [5.0–34.0] daysMedian [IQR]; narrative prints 36.5 for the first upper quartilep=0.8635; nonsignificant
- ICU stay among survivors
- 29.0 [12.0–36.0] versus 36.5 [21.8–54.0] daysSurvivor subset; selection may bias comparisonp=0.0015
- Infection and antioxidant activity
- Infections comparable; antioxidant activity remained below normal
Study notes · methods, sources and limitations
Participants or model 104 severe combined-trauma patients
Design 104 trauma patients: 38 Dalargin, 66 controls; allocation safeguards unverified.
Important limitations
- Unequal groups; randomized allocation and blinding not established in this appraisal. Biomarker changes do not prove improved survival; survivor-only length of stay requires caution.
- Dalargin versus standard care throughout. Unequal groups and unverified assignment prevent causal inference. No survival benefit established.
Annals of Critical Care. 2023;(4):185–196 · Publication record
Randomized study in people · 2017
[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].
- Insulin change
- −22.4% versus −6.5%Dalargin + standard care versus standard care3 monthsp<0.001 for Dalargin changes; p<0.05 for standard-care changes
- TNF-α change
- −55% versus −9.4%Same randomized treatment groups3 months
- IL-6 change
- −56.3% versus −6.1%Same groups3 months
Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.
More reported outcomes
- Triglyceride change
- −27.2% versus −17.4%Same groups3 months
- HDL cholesterol change
- +17.4% versus +10.3%Same groups3 months
- Other Dalargin-arm changes
- β-endorphin +32.6%; leptin −36.1%; cortisol −23.9%; LDL cholesterol −14%Within-arm changes; not placebo-adjusted effects3 monthsp<0.001 reported
Study notes · methods, sources and limitations
Participants or model 123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome
Design 123 coronary-heart-disease patients with metabolic syndrome randomized to standard care (63) or adjunctive Dalargin (60); 84 additional CHD patients without metabolic syndrome formed a separate comparison group.
- Studied schedule
- 2 mg/day for 10 days; 3 courses across 3 monthsReported study regimen
Important limitations
- Biomarker outcomes do not establish fewer cardiovascular events. Blinding and allocation concealment are not described in the abstract. Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
- Percentages are within-group changes. The abstract does not provide the interaction test, event rates or a cardiovascular risk reduction.
Klinicheskaia meditsina · Indexed abstract
Thymalin + Dalargin: what was actually studied?
The 1998 ulcer report is a combination-related lead with unresolved treatment arms. The separate 1988 wound paper reports threefold fibroblast mitotic activity in rats; it does not establish threefold faster healing or synergy with Thymalin.
Study methods, measured results and source limits ↗ · 1998 human-study results ↗
Performance research in context
Sports performance evidence map ↗ Military & occupational evidence map ↗
- Compound class
- Synthetic enkephalin analogue
- Research collection
- Opioid-peptide cytoprotection · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
A 104-patient trauma comparison; hearing patent case material kept separate; historical 120-patient ulcer immune report, with combination treatment arms unresolved
Study methods
Receptor assays, animal dissertations, human comparison and patents
Independent replication
Independent clinical replication not established by this collection
Source access
Indexed abstracts, publisher text, patent tables and dissertation transcriptions
Safety evidence
Delivery and clinical context matter; long-term and combination safety remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 5 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Completed trial · registry only · 2020
Registered Dalargin and Leitragin COVID-19 trial
The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.
Study notes and original source
Registered Dalargin and Leitragin COVID-19 trial
· Trial registry
Burnasyan Federal Medical Biophysical Center · ClinicalTrials.gov NCT04346693.
The registry lists a completed 320-person Phase III trial with standard care, Dalargin, Leitragin and combination arms. No results are posted in the registry.
Results and tables
Reported findings and study design
The patent gives no measured outcomes
Open-label randomized parallel-group study. The registry provides actual overall enrollment and describes four planned groups.
Dose, route and schedule
All four arms received the study’s background care. The add-on arms specify Dalargin 1 mg intramuscularly daily for 10 days, Leitragin 10 mg by inhalation daily until pulmonary complications resolved, or both.
Protocol source ↗ · ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Actual enrollment | 320 participants |
Arm descriptions as specified by the sponsor
| Arm | Listed group size | Study intervention alongside background care |
|---|---|---|
| Comparison | 80 | Background care only |
| Dalargin | 80 | 1 mg IM daily for 10 days |
| Leitragin | 80 | 10 mg inhaled daily until pulmonary complications resolved |
| Combination | 80 | Dalargin plus Leitragin on the same schedules |
Arm sizes in the protocol descriptions. Arm-level enrollment and outcomes are unavailable.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 320 actual enrollees reported. The four arm descriptions list 80 participants apiece.
- Source reviewed
- ClinicalTrials.gov record and sponsor-submitted enrollment and intervention fields.
Study limitations
- Intervention labels and dose descriptions conflict in the registry. The arm summaries follow the detailed descriptions. The listed treatment reflects 2020 study methods.
Reviewed 2026-11-15.
Animal research · 2014
Cortexin and Dalargin during a 21-day rat swimming series
Cortexin and Dalargin were given to separate rat arms.
Study notes and original source
Cortexin and Dalargin during a 21-day rat swimming series
· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9
Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations
N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9
First-swim means reached 227.25 s with Cortexin and 218.0 s with Dalargin on day 21, versus 71.9 s in controls. Starting means already differed.
Results and tables
Reported findings and study design
First-swim means reached 227.25 s with Cortexin and 218.0 s with Dalargin on day 21, versus 71.9 s in controls. Starting means already differed.
Repeated forced swimming with a 7%-body-mass load. Three swims per test session measured persistence and recovery. Tests before treatment, on days 7, 14 and 21, and one week after dosing.
Population or model Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.
Dose, route and schedule
Daily rectal Cortexin 5 mg/kg or Dalargin 0.56 mg/kg for 21 days, in separate arms.
Protocol source ↗ · Original publication and selected methods and results checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin · first swim | 84.3±3.9 → 227.25±4.5 s | Day 0 to 21. Second and third day-21 swims: 159.0±4.28 and 204.6±10.9 s. |
| Dalargin · first swim | 79.7±5.4 → 218.0±6.6 s | Day 0 to 21. Second and third day-21 swims: 187.3±5.4 and 181.6±6.7 s. |
| Control · first swim | 63.8 → 71.9±3.9 s | Day 0 to 21. Control rose to 91.4±3.3 s on day 28. |
| Cortexin · recovery index | Transient deterioration at day 14 | Recovery and first-swim duration are separate outcomes. |
The arms compare the peptides individually. They do not test a Cortexin–Dalargin combination.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.
- Source reviewed
- Original publication and selected methods and results checked
Study limitations
- Unequal baseline results, non-equivalent doses and repeated training exposure limit between-group interpretation.
Reviewed 2026-11-09.
Comparison in people · 1998
The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
Study notes and original source
The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin
Thymalin and Dalargin mentioned within complex therapy; simultaneous administration and the treatment arms are unresolved. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Lukash NV, Polishchuk TF, Ludan VV · Lik Sprava. 1998;(3):56-58. PMID 9695565
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
Results and tables
Reported findings and study design
Findings described in words
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| T-cell immune measurements | Improvement toward healthy-reference levels reported; no numerical treatment effect or arm-specific denominator supplied | E-rosette and theophylline-sensitive/resistant assays; healthy donors are reference controls, not an untreated ulcer-treatment arm |
| Unchanged index and source inconsistency | The abstract says TFS-RFC did not differ from controls before or after treatment | The same abstract uses inconsistent TPP/TPS/TFP/TFS abbreviations and also lists reduced indices; exact subset interpretation requires the original paper |
| Clinical cohort | 120 ulcer patients and 30 healthy donors | These totals do not establish randomization, treatment-group sizes or simultaneous dual treatment |
| Clinical healing and safety | No ulcer-closure rate, relapse rate, adverse-event count or combination-specific clinical endpoint in the abstract | |
| Dose, route and schedule | Not supplied in the abstract |
This is the direct human research lead, with unresolved exposure assignment. It is not a verified combination trial or a validated healing regimen. The neutral sentence and inconsistent abbreviations remain visible.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Original treatment-arm table, doses, routes, concurrent care, allocation and follow-up not recovered.
- Historical rosette subpopulations must not be relabeled as modern flow-cytometry CD4/CD8 or regulatory T-cell measurements.
- Healthy donor references do not control for other ulcer treatments. The abstract does not prove simultaneous coadministration, additive benefit or synergy.
Reviewed 2026-11-08.
Animal research · 1995
The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
Study notes and original source
The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer
Thymalin, Dalargin and experimental Mucosalin, a pig-gastric-mucosal extract; compared preparations, not a verified simultaneous pair. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Lukash NV, Polishchuk TF · Lik Sprava. 1995;(1-2):53-55. PMID 7483545
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
Results and tables
Reported findings and study design
Findings described in words
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Relative protective activity | Mucosalin > Dalargin > Thymalin, as ranked in the abstract | Qualitative ranking; no effect size, uncertainty or pairwise significance provided |
| Animal program | 80 male Wistar rats in total | Not 80 rats per peptide and not a human cohort |
| Combination exposure | No simultaneous Thymalin plus Dalargin administration established by the abstract |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Dose, route, duration, individual arm sizes and lesion-score tables are unavailable in the abstract.
- Mucosalin is a separate experimental extract; its result is not transferred to either Thymalin or Dalargin.
- Comparative animal protection is not evidence of synergy or human ulcer healing.
Reviewed 2026-11-08.
Animal research · 1987
Blood flow in skin wound tissue and systemic hemodynamics as affected by a collagen-dalargin complex
A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.
Study notes and original source
Blood flow in skin wound tissue and systemic hemodynamics as affected by a collagen-dalargin complex
Collagen–Dalargin complex; not assumed equivalent to free Dalargin, every local formulation or a Thymalin combination. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Medvedev OS, Khulup GIa, Spevak SE, Istranov LP, Titov MI · Biull Eksp Biol Med. 1987;104(12):651-654. PMID 2446676
A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.
Results and tables
Reported findings and study design
Findings described in words
A collagen–Dalargin preparation increased wound-granulation blood flow and capillary formation, while capillary blood flow in unaffected tissue was unchanged.
Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
Population or model Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Wound microcirculation | Increased granulation-tissue blood flow, new capillary formation and lower vascular resistance described | Microsphere method; no numerical flow values or effect uncertainty in the abstract |
| Unaffected tissue | No effect on capillary blood flow reported | Neutral tissue-specific finding |
| Preparation boundary | The tested preparation was a collagen–Dalargin complex | No Thymalin co-treatment or general formulation equivalence established |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Rat skin-wound/granulation-tissue experiment; sample sizes unavailable in the indexed abstract.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Original carrier controls, dose, route, sample sizes and numerical hemodynamic tables require full text.
- A local wound-flow finding is not a general increase in systemic circulation or proof of clinical healing.
Reviewed 2026-11-08.
Animal research · 1988
Effects of opioid peptide dalargin on reparative processes in wound healing
The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.
Fibroblast proliferation · 3-fold increase in mitotic index reported · Rat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable
Study notes and original source
Effects of opioid peptide dalargin on reparative processes in wound healing
Dalargin by intraperitoneal injection and local application; route-specific effect magnitudes not separated in the abstract. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Shekhter AB, Solov'eva AI, Spevak SE, Titov MI · Biull Eksp Biol Med. 1988;106(10):487-490. PMID 3191245
The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.
Results and tables
Reported findings and study design
Reported findings
The abstract reports a threefold fibroblast mitotic-index increase, capillary growth and faster maturation/epithelialization in rat wounds. It does not give a numerical reduction in healing days.
Rat skin wounds; group sizes and observation times absent from the abstract.
Population or model Rat skin wounds; group sizes and observation times absent from the abstract.
Dose, route and schedule
Intraperitoneal injection and local Dalargin application; dose, frequency and observation duration unavailable in the abstract.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fibroblast proliferation | 3-fold increase in mitotic index reported | Rat wound tissue; raw indices, uncertainty and route-specific contrasts unavailable |
| Repair outcomes | Capillary growth, granulation/scar maturation and epithelialization described as faster | No verified numerical days-to-closure estimate; threefold mitosis is not threefold faster healing |
| Reported routes | Intraperitoneal injection and local application | Dose, frequency and duration not supplied by the abstract |
| Safety | No adverse-event counts or long-term scarring outcomes supplied |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Rat skin wounds; group sizes and observation times absent from the abstract.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- No dose, denominator, exact observation schedule or numerical healing-time table in the abstract.
- Separate single-agent animal research; it does not establish Thymalin–Dalargin synergy or human wound benefits.
Reviewed 2026-11-08.
Lab research · 1987
Importance of opiate receptor ligands in regulating lymphocyte proliferative activity
Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.
Study notes and original source
Importance of opiate receptor ligands in regulating lymphocyte proliferative activity
Dalargin and other opioid ligands tested in separate culture conditions. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Zozulia AA, Voronkova TL, Patsakova E, Ivanushkin AM · Farmakol Toksikol. 1987;50(3):58-59. PMID 3038604
Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.
Results and tables
Reported findings and study design
Findings described in words
Dalargin inhibited phytohemagglutinin-driven lymphocyte proliferation at 10⁻¹²–10⁻⁷ M; naloxone blocked that effect.
Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
Population or model Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
Dose, route and schedule
Dalargin 10⁻¹²–10⁻⁷ M in stimulated human lymphocyte cultures; the abstract lists naloxone 10⁻⁸–10⁻⁶ M. Exposure duration unavailable.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mitogen-induced proliferation | Inhibited by Dalargin at 10⁻¹²–10⁻⁷ M | Human-cell assay; no numerical inhibition percentage or donor count supplied |
| Naloxone contrast | Blocked the reported Dalargin-associated inhibition | Assay-specific pharmacology, not proof of a beneficial immune effect in people |
| Experimental concentration | Dalargin 10⁻¹²–10⁻⁷ M; naloxone range 10⁻⁸–10⁻⁶ M | Culture concentrations, not human doses; timing unavailable |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Cultured human peripheral-blood lymphocytes stimulated with polyclonal mitogens; donor and replicate counts unavailable.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- No donor count, numerical response curve or effect uncertainty in the abstract.
- Opioid ligands and mitogen conditions differ; no Thymalin combination or human immune outcome was tested.
Reviewed 2026-11-08.
Lab research · 1987
Immunomodulating action of neuropeptides in in vitro systems
Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.
Study notes and original source
Immunomodulating action of neuropeptides in in vitro systems
Dalargin and leu-enkephalin investigated as separate ligands. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Karpov RS, Beĭko VA, Vasil'chenko EM · Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128
Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.
Results and tables
Reported findings and study design
Findings described in words
Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.
Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
Dose, route and schedule
Dalargin 0.1 µg/mL in the leukocyte-migration assay. A complete concentration/time protocol for the proliferation assay is not given.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lymphocyte proliferation | Increase or decrease depended on baseline responsiveness to phytohemagglutinin | Bidirectional culture response; not a uniform immune stimulant |
| Leukocyte migration | Inhibition reported with Dalargin 0.1 µg/mL | Culture assay; numerical migration change unavailable |
| Serum correlation component | Serum from 55 patients; endogenous leu-enkephalin inversely correlated with mitogen responsiveness | Observational association, not 55 patients receiving Dalargin |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- In-vitro donor counts, response magnitudes and exposure duration unavailable in the abstract.
- Observational serum results and drug-exposure experiments are different components.
Reviewed 2026-11-08.
Lab research · 1988
Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes
Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.
Study notes and original source
Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes
Dalargin preincubation of human lymphocytes; no Thymalin treatment. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Aleksandrova EN, Nasonov EL, Vinogradov VA, Titov MI · Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025
Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.
Results and tables
Reported findings and study design
Findings described in words
Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.
Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
Population or model Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
Dose, route and schedule
Human lymphocytes preincubated with Dalargin 10⁻¹⁴–10⁻⁸ M; naloxone 10⁻⁶ M tested separately. Incubation duration and full dose–response table unavailable.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| NK-cell function | More effector–target contacts and active NK cells described | K-562 laboratory target assay; no clinical cancer outcome or numerical benefit estimate |
| Experimental exposure | Dalargin preincubation at 10⁻¹⁴–10⁻⁸ M | Duration unavailable; the later peak-range sentence has a malformed exponent and is not reconstructed |
| Naloxone finding | At 10⁻⁶ M, naloxone itself enhanced target contacts and lytic activity in this assay | Different response from the 1987 proliferation-blockade experiment; receptor effects are assay-dependent |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Original response curves, donor counts and route-independent safety require full text.
- One activity-peak exponent is malformed in the indexed abstract; no corrected range is asserted.
- Natural cytotoxicity in vitro is not anticancer efficacy.
Reviewed 2026-11-08.
Lab research · 1994
The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity
The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.
Study notes and original source
The effect of endogenous opioid peptides and their synthetic analogs on T-cell immunity
Met-/leu-enkephalins, DAGO, DADLE and Dalargin tested as distinct opioid ligands. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Korostelev SA, Isakova KL, Shchegolev AI, Uteshev BS · Eksp Klin Farmakol. 1994;57(1):57-61. PMID 8142868
The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.
Results and tables
Reported findings and study design
Findings described in words
The abstract describes an opioid-class stimulation maximum when added 24–48 hours after culture initiation under suboptimal antigen conditions. It does not isolate a quantitative Dalargin-specific maximum.
Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Population or model Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
Dose, route and schedule
The abstract describes opioid addition 24–48 hours after culture initiation for a class-level maximum; Dalargin-specific concentration and timing are not fully resolved.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Timing-dependent culture response | Largest opioid-class stimulation described after addition at 24–48 hours | Class-level statement under suboptimal antigen conditions; not a Dalargin-specific human schedule |
| Ligand differences | Selective mu- and delta-ligands had effects in different directions | DAGO and DADLE findings are not assigned to Dalargin |
| Dalargin-specific quantitative gap | No separate numerical Dalargin effect or concentration table provided |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Alloantigen-stimulated mixed-lymphocyte cultures; species, sample counts and quantitative Dalargin-specific response unresolved in the abstract.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Concentrations, denominators, uncertainty and precise ligand-specific contrasts require the full paper.
- Culture timing is not a clinical administration schedule and does not establish Thymalin combination benefit.
Reviewed 2026-11-08.
Lab research · 1994
The effect of endogenous opioid peptides and their synthetic analogs on the activity of natural killer cells
Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.
Study notes and original source
The effect of endogenous opioid peptides and their synthetic analogs on the activity of natural killer cells
Dalargin and other opioid peptides tested separately. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Uteshev BS, Korostelev SA, Isakova KL, Shchegolev AI · Eksp Klin Farmakol. 1994;57(1):55-57. PMID 8142867
Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.
Results and tables
Reported findings and study design
Findings described in words
Dalargin and endogenous opioid peptides enhanced NK-cell cytolytic activity in the abstract; no numerical effect size was supplied.
Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
Population or model Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| NK-cell cytolysis | Increase described with Dalargin and endogenous peptides | Cell-culture endpoint, not a clinical antitumor response |
| Numerical extraction gap | No concentration, effect magnitude, denominator or uncertainty in the abstract |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Natural-killer-cell culture assays; the indexed record includes mouse/animal terms, not a human treatment cohort. Sample counts unavailable.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- The concentration in the 1988 human-cell assay applies only to that experiment.
- No Thymalin combination, human treatment or cancer-survival benefit established.
Reviewed 2026-11-08.
Comparison in people · 1991
Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer
After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.
Study notes and original source
Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer
Dalargin compared with conventional therapy; no Thymalin coadministration established. · Original journal publication
Format: Original indexed abstract · Reviewed: Indexed abstract and citation checked; full original outcome tables not recovered
Timoshin SS, Alekseenko SA, Shtuka AA · Klin Med (Mosk). 1991;69(3):75-77. PMID 2067344
After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.
Results and tables
Reported findings and study design
Findings described in words
After 20 days, Dalargin was associated with a higher index of DNA-synthesizing epithelial nuclei in fundal and duodenal-bulb mucosa than conventional care. No numerical index was supplied.
Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
Population or model Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
Dose, route and schedule
Twenty-day Dalargin course. Dose, route and administration frequency are unavailable in the abstract.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mucosal DNA-synthesis marker | Significant increase in labelled epithelial nuclei described after Dalargin | Fundal and duodenal-bulb biopsies; exact indices, p-value and group sizes unavailable · 20 days |
| Clinical endpoint gap | No numerical ulcer-closure, relapse, symptom or safety comparison in the abstract |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Duodenal-ulcer patients treated with Dalargin or conventional spasmolytic/antacid care; group sizes unavailable in the abstract.
- Source reviewed
- Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Study limitations
- Historical active comparator; allocation, masking and other ulcer care require full text.
- A proliferation marker is not a demonstrated clinical healing or combination-treatment benefit.
Reviewed 2026-11-08.
Animal research · 2007
On the character of Dalargin’s influence on duodenal secretory epithelial cells
The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.
Study notes and original source
On the character of Dalargin’s influence on duodenal secretory epithelial cells
Dalargin alone; Thymalin was not tested. · Original animal journal publication
Format: Original publisher PDF indexed full text; original page images not visually inspected · Reviewed: Methods and selected numerical narrative outcomes checked in the original indexed four-page paper
V. L. Mogilnaya · Uspekhi sovremennogo estestvoznaniia. 2007;(12, part 1):33–36.
The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.
Results and tables
Reported findings and study design
Reported findings
The paper reports phase- and tissue-dependent mucin changes: a villus mucin-production index rose from a reported baseline 60.56±4.01 to 110.2±0.75 by day 3; early crypt and trefoil responses were mixed.
Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
Population or model Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
Dose, route and schedule
Dalargin 24 µg/kg every 12 hours in the intact-animal parenteral group; the ulcer group received subcutaneous Dalargin every 12 hours without restating its dose. Intact-group assessments days 1, 2, 4 and 7; ulcer-group days 1–3. No missing ulcer-group dose is silently filled in.
Protocol source ↗ · Original methods, p.33; route and dose statements kept source-specific
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Villus mucin-production index | Reported baseline 60.56±4.01; 110.2±0.75 at day 3 with Dalargin | Histochemical index, source-specific units; not an 82% clinical healing benefit. Original uncertainty type not defined. |
| Separate untreated-ulcer reference | 57.7±0.95 reported for villus mucin production without Dalargin | Conclusion gives this reference separately; no matched-time treatment effect or confidence interval inferred |
| Crypt mucin response in ulcer conditions | No response to Dalargin over the first three days described | Neutral location-specific finding, despite the favorable villus narrative |
| Intact-mucosa early crypt coefficient | 2.19±0.07 in controls versus 1.85±0.1 after Dalargin | Neutral-mucin cytochemical coefficient; an early decrease, not uniform stimulation · Day 1 · p<0.01 |
| Trefoil-peptide signal | Early fall after Dalargin in ulcer-bearing animals, followed by return toward initial levels on days 2–3 | Qualitative histochemistry; no clinical consequence established |
This paper extends the mucosal-repair hypothesis while showing phase- and compartment-dependent responses. It is not a Thymalin combination experiment or a quantified clinical healing trial.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Male Wistar rats, intact mucosa and experimental duodenal-ulcer conditions; three described groups, but animal counts not reported.
- Source reviewed
- Original publisher indexed PDF pp.33–36, including the untreated-ulcer value and neutral/early-decrease passages. Sample sizes and the type of ± uncertainty are not established. Original PDF page images unavailable.
Study limitations
- No animal group sizes, masking or complete statistical plan supplied.
- Histochemical indices are surrogate tissue measures, not clinical ulcer-healing percentages.
- The source gives both a general baseline and an untreated-ulcer reference; they are not interchangeable control time points.
- Intact and ulcer-bearing animals show different time courses. Dose is explicitly printed for the intact group but not repeated for the ulcer group.
Reviewed 2026-11-08.
Animal research · 2016
Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Study notes and original source
Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides
dalargin · Original journal publication
Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered
Pinaeva OG, Sazonova EN, Lebed'ko OA, Timoshin SS · Bulletin of experimental biology and medicine. 2016;162(2):203. PMID 27909965
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Results and tables
Reported findings and study design
Findings described in words
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Dalargin or a non-opiate Leu-enkephalin analogue, 100 µg/kg on postnatal days 2–6; day-7 liver growth, proliferation, nucleolar and redox assays.
Population or model Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dalargin | Reported normalization of gravimetric, proliferation and hepatocyte nucleolar measures | |
| Non-opioid analogue: incomplete effect | Gravimetric and nucleolar parameters not normalized; proliferating-cell pool increased | Related analogue is not Dalargin |
| Redox outcomes | Both preparations reduced free-radical oxidation and improved antioxidant defenses; numerical effects unavailable |
Postnatal animal treatment, not maternal administration or human neonatal efficacy. Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function. The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract
- Source reviewed
- Indexed original abstract; full methods and outcome tables not recovered
Study limitations
- Postnatal animal treatment, not maternal administration or human neonatal efficacy.
- Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function.
- The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.
Reviewed 2026-11-08.
Comparison in people · 2025
Dalargin plus carbohydrate loading during oropharyngeal cancer surgery
The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.
Study notes and original source
Dalargin plus carbohydrate loading during oropharyngeal cancer surgery
Dalargin during perioperative care plus preoperative carbohydrate loading · Original clinical journal publication
Format: Original publisher abstract in journal PDF · Reviewed: Publisher abstract checked; numerical outcome tables not yet extracted
D. N. Vasiliev, D. E. Kulbakin, E. L. Choynzonov, S. V. Avdeev, A. A. Lee, I. P. Puteev, A. V. Pak, A. V. Kushner · Siberian Journal of Oncology. 2025;24(1):29–38
The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.
Results and tables
Reported findings and study design
Findings described in words
The combined protocol was associated with lower stress-hormone responses, more favorable aerobic-metabolism measures and fewer postoperative complications. The abstract gives no figures for these differences.
58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Stress-hormone response and metabolism | Lower stress-hormone release and more favorable aerobic-metabolism measures reported with the combined protocol | Dalargin plus carbohydrate loading versus standard perioperative care; numerical changes not available in the abstract · Perioperative assessments |
| Postoperative complications | Fewer complications reported; counts, types and effect uncertainty not extracted | No numerical risk reduction inferred |
| Study groups | 29 combined-intervention versus 29 standard-care patients; 58 total |
A combined perioperative intervention, not isolated Dalargin efficacy or an anticancer trial. Reported differences remain qualitative until outcome tables can be checked.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 58 surgical patients with oropharyngeal cancer; 29 combined-intervention and 29 standard-care patients
- Source reviewed
- Original journal abstract; no complete risk-of-bias appraisal or verification of full outcome tables.
Study limitations
- Dalargin was combined with carbohydrate loading; the independent contribution of each is unresolved.
- Randomization, masking and allocation concealment were not established in the abstract.
- Numerical complication counts, effect sizes and uncertainty require the original outcome tables.
- Perioperative metabolic findings do not demonstrate improved tumor control or cancer survival.
Reviewed 2026-11-06.
Experiment described in a patent · 2024
Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1
The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.
Reported clinical improvement · 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placebo · Broad symptom-based outcome; no prespecified responder threshold reported · After the 30-day course
Study notes and original source
Dalargin: menopausal symptoms and six-month follow-up — RU2821826C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Борис Юльевич Чебураков · RU2821826C1 · patent family RU2821826C1
The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.
Results and tables
Reported patent results
Reported findings
The inventor reports symptom improvement after Dalargin with persistence at six months. Pineamin and IPH GAA are background references, not treatments in this comparison.
Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.
Population or model Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported clinical improvement | 15/15 (100%) with Dalargin versus 5/8 (62.5%) with placebo | Broad symptom-based outcome; no prespecified responder threshold reported · After the 30-day course |
| Six-month follow-up | All 15 Dalargin recipients reportedly retained improvement; all 8 placebo recipients returned to baseline | Follow-up completeness and independent assessment not established · 6 months |
| Illustrative patient: hot flashes | 15–20/day at baseline, 3–5/day at day 15, absent at day 30 | One 54-year-old patient; not a group mean · Days 15 and 30; benefit reported at 6 months |
| Reported tolerability | No complications or side effects reported | Small patent series; systematic adverse-event ascertainment not described |
Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent report of 23 women aged 45–55: Dalargin n=15 versus saline placebo n=8, treated for 30 days in 2022–2024. Randomization and masking are not described.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The small unequal groups, undefined response criteria and unverified allocation and masking prevent an established treatment effect.
- Unequal small groups, undefined improvement criteria, no documented allocation concealment or blinding, and no statistical estimates. These are inventor-reported observations, not established efficacy. The unrelated IPH GAA percentages are not Dalargin or Pineamin results.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2021
Dalargin: nasal respiratory-infection use and formulation — EP3556377B1
The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.
Donor-cell cytokines · Reduced stimulated IL-1, IL-6 and TNF-α production reported · In-vitro experiment using cells from 20 donors; exact figure percentages not transcribed
Study notes and original source
Dalargin: nasal respiratory-infection use and formulation — EP3556377B1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Evgeny Alexandrovich Chertorizhsky, Mikhail Vladimirovich Ovchinnikov, Aleksey Viktorovich Kleimenov · EP3556377B1 · patent family 64328036
The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.
Results and tables
Reported patent results
Findings described in words
The patent reports reduced stimulated inflammatory-cytokine production and altered innate-cell activity.
Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.
Population or model Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Donor-cell cytokines | Reduced stimulated IL-1, IL-6 and TNF-α production reported | In-vitro experiment using cells from 20 donors; exact figure percentages not transcribed |
| Animal innate-cell findings | Increased phagocytic activity described; no detected difference between the tested routes | A laboratory result, not demonstrated clinical infection recovery |
Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Dalargin preclinical immune/inflammatory experiments, including cells from 20 healthy donors; these donors did not receive the proposed treatment.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A granted formulation or use claim does not establish clinical antiviral benefit.
- Human-derived cells are not a human treatment trial. Cytokine and cell-function results cannot establish clinical antiviral effectiveness, route equivalence or safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2011
GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1
The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.
Study notes and original source
GHK plus Dalargin: 2011 bone-repair patent — RU2429002C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Виктор Юрьевич Чердаков, Михаил Юрьевич Смахтин, Григорий Михайлович Дубровин, Игорь Иванович Бобынцев, Виктор Тарасович Дудка, Максим Евгеньевич Долгинцев, Алексей Анатольевич Крюков, Вадим Теймуразович Корошвили, Ирина Михайловна Соболева, Евгений Николаевич Кононец, Андрей Евгеньевич Белых, Ольга Игоревна Иванова · RU2429002C1 · patent family 44758621
The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.
Results and tables
Reported patent results
Findings described in words
The authors describe more advanced early bone repair with GHK plus Dalargin than with saline or either peptide alone. The evidence is qualitative radiography and histology.
Wistar rat fracture model; groups of 8–10 animals; saline, copper-free GHK, Dalargin and combined treatment; assessment at day 10.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combined treatment: radiographic appearance | Fracture line described as barely visible with the combination; still visible but less pronounced with either peptide alone | Versus saline and single-peptide groups; no numerical radiographic score or uncertainty reported · Day 10 |
| Combined treatment: histological appearance | New bone formation and remodeling toward compact bone were described as more advanced in the combination group | Descriptive morphology; no quantitative histomorphometry or factorial interaction test · Day 10 |
| GHK versus Dalargin alone | No visible morphological difference reported between the two single-peptide groups | A neutral qualitative comparison, not a demonstration of equivalence · Day 10 |
| Healing time, strength and safety | No measured union-time advantage, biomechanical strength estimate or formal adverse-event series reported | A day-10 observation does not mean fractures healed ten days faster |
| Reported group sizes | 8–10 rats per group; exact group denominators not assigned | |
| Reported experimental course | Daily GHK plus Dalargin for ten days; other groups received single peptides or saline |
Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.
Source for these results ↗ · Reviewed 2026-11-07
- Population / setting
- Wistar rat fracture model; groups of 8–10 animals; saline, copper-free GHK, Dalargin and combined treatment; assessment at day 10.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The fracture experiment tested the combination in rats. No measured shortening of healing time or biomechanical strength was reported.
- Early rat bone-repair observations do not establish clinical fracture healing or quantitatively validated synergy. The preparation was copper-free GHK plus Dalargin. Related author publications may reuse the research program.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-07.
Experiment described in a patent · 1991
Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Study notes and original source
Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova · SU1674849A1 · patent family 21434935
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Results and tables
Reported patent results
Reported findings
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
Population or model Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Alternative-treatment examples | Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14% | One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects |
| Dalargin case: immune measures | T-suppressor index 9%→25%; T-helper index 71%→55% | Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements |
| Thymalin case: immune measures | T-suppressor index 33%→30%; T-helper index 35%→57% | Example 3; B cells 32%→13% |
| T-activin case: immune measures | T-suppressor index 40%→34%; T-helper index 31.4%→52% | Example 1; B cells 28.6%→14% |
| Clinical course in selected cases | Discharge reported on day 19 with Dalargin and day 21 with Thymalin or T-activin | Individual clinical descriptions; no matched control or causal days-saved estimate |
| Russian-text peptide schedules | Dalargin 1 mg intramuscularly twice daily for 5 days; Thymalin 5 mg intramuscularly once daily for 4 days; or T-activin 50 µg subcutaneously daily for 5 days | Alternative historical treatments with photochemotherapy, not a combined or current prescribing regimen |
| Translation and extraction gaps | English abstract mistranslates T-activin as 50 mg; one Thymalin case mistranslates frequency as four times daily | Russian text and course totals specify 50 µg and once daily, respectively. Patent PDF and aggregate comparison table not recovered. |
Three selected patent cases: before → after
| Historical immune measure | Dalargin, example 2 | Thymalin, example 3 | T-activin, example 1 |
|---|---|---|---|
| B-lymphocytes (%) | 10→20 | 32→13 | 28.6→14 |
| T-suppressor index (%) | 9→25 | 33→30 | 40→34 |
| T-helper index (%) | 71→55 | 35→57 | 31.4→52 |
Case descriptions, not study-arm means; n=1 selected patient per preparation. Photochemotherapy was concurrent. Historical subset labels do not establish modern regulatory-T-cell phenotypes.
This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
- This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-08.
Animal research · 2020
PPK-V versus Cortexin, Semax and Dalargin: rat peptide-profile study
Hypoxia and swimming results came from separate animal cohorts. The original raw times and dose statements are retained below.
Study notes and original source
PPK-V versus Cortexin, Semax and Dalargin: rat peptide-profile study
Commercial Cortexin, Semax and Dalargin; their combinations; experimental calf-brain hydrolysates PPK-A, B, V, G, D and E. PPK-V is cortex-derived; PPK-B is brainstem-derived. · Original animal and analytical journal research
Format: Original publisher indexed HTML/PDF text; matching tables in recovered 2019 monograph · Reviewed: Original indexed methods and Tables 1–7 checked; matching monograph pp.294–296 visually inspected. Original journal PDF page images not recovered.
E. B. Shustov, D. Yu. Ivkin, A. S. Ivkina, A. E. Kim, S. L. Lublin, M. S. Nesterov · Search for the optimal mass profile of neuropeptides for the implementation of antihypoxic and activating actions. Pharmacy Formulas. 2020;2(4):72–81.
Table 2 reports PPK-V hypoxia time 552±44 s and swimming time 289±66 s; Cortexin 201±11 s and 172±44 s; displayed controls 95±3 s and 135±6 s. Unequal doses and pooled experiments prevent a reliable potency or superiority claim.
Results and tables
Reported findings and study design
Reported findings
Raw times and standardized T-scores are shown separately below. Larger reported values are not a dose-matched estimate of superiority.
Ten rats per group; males for chamber hypoxia (time to agonal signs) and females for loaded swimming (time to exhaustion). Single rectal exposure one hour before testing; saline vehicle controls. Separately performed experiments were standardized and pooled.
Population or model Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.
Dose, route and schedule
Single rectal administration one hour before testing. Methods list Dalargin 0.56 mg/kg, Semax 0.22 mg/kg, Cortexin 1 mg/kg and experimental peptide preparations 2.5 mg/kg. Combination components were not dose-reduced. The discussion instead gives an overall range up to 8.06 mg/kg for PPK-E; this discrepancy is unresolved.
Protocol source ↗ · Original methods and dose-analysis discussion; animal protocol, not human dosing
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| PPK-V: hypoxia time | 552±44 s; Cortexin 201±11 s; displayed control 95±3 s | Table 2, M±m; separate experiments and unequal doses; no verified pairwise PPK-V-versus-Cortexin p-value |
| PPK-V: loaded-swimming time | 289±66 s; Cortexin 172±44 s; displayed control 135±6 s | Table 2, M±m; 10% body-weight load; female cohort differs from the male hypoxia cohort |
| Route, timing and nominal PPK dose | Rectal, once, one hour before testing; experimental preparations 2.5 mg/kg in methods | Discussion maximum: 8.06 mg/kg for PPK-E; individual complex exposures not fully reconciled |
| Cortexin alone | Hypoxia 201±11 s; loaded swimming 172±44 s | Displayed controls 95±3 s and 135±6 s; M±m; methods dose 1 mg/kg rectally |
| Semax alone | Hypoxia 218±23 s; loaded swimming 221±60 s | Displayed controls 95±3 s and 135±6 s; M±m; methods dose 0.22 mg/kg rectally |
| Dalargin alone | Hypoxia 170±8 s; loaded swimming 201±12 s | Displayed controls 95±3 s and 135±6 s; M±m; methods dose 0.56 mg/kg rectally |
| Combination comparisons | Cortexin + Dalargin: 250±15 s / 275±62 s; Semax + Dalargin: 293±25 s / 198±10 s | Hypoxia / swimming; M±m. Components were not dose-reduced. The combined Semax/Dalargin swimming mean was below Semax alone (221±60 s); no formal synergy demonstrated. |
| 5–10 kDa fraction and hypoxia | D=0.44; p=10⁻²⁰ | Table 5 pooled factor analysis; association does not identify the active molecule or establish causation |
| 5–10 kDa fraction and swimming | D=0.01; p=0.97 | Table 6: no association detected in this analysis; the hypoxia finding is not a general performance result |
| Dose as a confounding factor | Reported dose-factor D=0.31 for hypoxia and D=0.40 for swimming | Table 4; composition and exposure varied together. The authors grouped doses across different preparations. |
| Mass-profile reporting gap | PPK-V fractions total 95.33%; Cortexin fractions total 98.37% | Calculated sums of Table 1 entries, not new laboratory results. Final bin heading >1 kDa conflicts with the narrative <1 kDa; no renormalization. |
| Safety and duration | No dedicated adverse-event counts, long-term follow-up or human PPK-V outcome supplied | An acute functional assay cannot establish a safe human regimen |
Table 2: raw times and T-scores kept separate
| Preparation | Hypoxia time (s), M±m | Hypoxia T-score, M±m | Swimming time (s), M±m | Swimming T-score, M±m |
|---|---|---|---|---|
| Saline control | 95±3 | 50±1 | 135±6 | 50±2 |
| Dalargin | 170±8 | 79±3 | 201±12 | 331±38 |
| Semax | 218±23 | 97±9 | 221±60 | 397±198 |
| Cortexin | 201±11 | 91±4 | 172±44 | 235±143 |
| Cortexin + Dalargin | 250±15 | 110±5 | 275±62 | 576±202 |
| Semax + Dalargin | 293±25 | 126±10 | 198±10 | 319±33 |
| PPK-A · hippocampus | 532±47 | 418±128 | 309±71 | 684±233 |
| PPK-B · brainstem | 538±23 | 418±73 | 186±27 | 280±90 |
| PPK-V · cortex | 552±44 | 460±130 | 289±66 | 621±215 |
| PPK-G · combined regions | 551±46 | 456±135 | 373±95 | 896±311 |
| PPK-D · combined regions | 498±30 | 298±87 | 369±92 | 886±300 |
| PPK-E · combined regions | 487±22 | 267±67 | 344±61 | 800±200 |
Original Table 2, p.76; matching 2019 monograph Table 110, p.296, visually inspected. n=10 per experimental group; separate sex-specific endpoint cohorts. Hypoxia time ends at agonal signs, not long-term survival; swimming time ends at exhaustion. Source M±m notation retained. Experiment-specific control normalization means T-score percentages are not raw-time improvements. No pairwise superiority p-values supplied here.
Table 1: reported mass-bin fractions
| Preparation | 10–30 kDa (%) | 5–10 kDa (%) | 1–5 kDa (%) | Final bin (%) |
|---|---|---|---|---|
| Dalargin | — | — | — | 98 |
| Semax | — | — | — | 100 |
| Cortexin | — | 33.37 | 62 | 3 |
| Cortexin + Dalargin | — | 5 | 18 | 77 |
| Semax + Dalargin | — | — | 75.55 | 24 |
| PPK-A | 14.88 | 38.73 | 39.11 | 4.77 |
| PPK-B | 2.54 | 43.5 | 49.04 | 4.92 |
| PPK-V | 11.39 | 35.39 | 43.15 | 5.4 |
| PPK-G | 30 | 36.27 | 25.51 | 5.58 |
| PPK-D | 13.83 | 25.63 | 23.54 | 35.48 |
| PPK-E | 12.7 | 20.23 | 48.87 | 18.2 |
Original Table 1, p.76; matching monograph Table 109, p.295, visually inspected. Final heading is printed >1 kDa, although the narrative describes <1 kDa; unresolved source inconsistency. — means a blank source cell, not verified zero. Fractions are not forced to total 100%. Molecular-mass bins do not identify peptide sequences or brain uptake.
This is a composition–activity hypothesis from pooled animal experiments. PPK-V is a distinct experimental cortex hydrolysate, not Cortexin or the brainstem PPK-B. Unequal exposures, source inconsistencies and matching earlier tables limit comparisons. No clinical superiority, formal combination synergy or intranasal PPK-V delivery has been established.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.
- Source reviewed
- The journal text and 2019 monograph reproduce the same outcomes and mass profiles (journal Tables 1–2 and book Tables 109–110, pp. 295–296). They represent one research program. Journal page images were unavailable for comparison.
Study limitations
- Different-sex cohorts and separate experiments contributed to the two endpoints; randomization is stated, but masking, allocation concealment and complete animal flow are not established.
- Doses were unequal, and the nominal experimental-preparation dose in methods conflicts with the discussion maximum. Table 2 does not resolve each complex’s actual exposure.
- Table 2 reports M±m; its uncertainty notation is retained without relabeling it as a verified SD. No preparation-specific pairwise p-values or confidence intervals establish PPK-V superiority over Cortexin.
- T-scores standardize results against experiment-specific controls. Their percentages and ratios cannot be interpreted as proportional increases in raw swim time or clinical performance.
- Table 1’s final bin is printed >1 kDa, while the narrative describes <1 kDa. Some fractions do not sum to 100%; blank cells are not assumed zero and values are not renormalized.
- The 5–10 kDa association is observational within the pooled analysis, not isolation of an active sequence or proof of brain penetration. Rectal results do not establish intranasal delivery.
- Matching 2019 and 2020 numerical tables are treated as one research program. No human PPK-V efficacy or long-term safety follows from these results.
Reviewed 2026-11-08.
Animal research · 2021
GHK, Dalargin and Thymogen in experimental bone fracture: 2021 rat study
At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.
Study notes and original source
GHK, Dalargin and Thymogen in experimental bone fracture: 2021 rat study
Copper-free GHK, Dalargin and Thymogen, singly and in pairs; local intraosseous administration · Original preclinical journal study; not a literature review
Format: Repository copy of the original nine-page journal article · Reviewed: Methods and results text checked; Table 1 (p.64) and Figure 5 (p.65) visually verified against rendered PDF pages
M. Yu. Smakhtin, I. I. Bobyntsev, V. T. Dudka, V. Yu. Cherdakov, A. O. Vorvul, A. A. Chulanova, A. M. Smakhtina · Humans and their Health / Chelovek i ego zdorovye. 2021;24(4):59–67
At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.
Results and tables
Reported findings and study design
Reported findings
Pairwise GHK combinations improved phagocytosis measures in fractured rats. GHK plus Dalargin also showed the strongest oxygen-dependent reserve pattern; GHK alone had a neutral reserve result. Bone repair was assessed descriptively.
Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified. Eight displayed groups: uninjured saline, fractured saline, three single peptides and three pairwise combinations. Assessments at day 10; local intraosseous exposure.
Dose, route and schedule
Ten-day local intraosseous exposure in the rat study: GHK and Thymogen 0.5 µg/kg, Dalargin 1.2 µg/kg, singly or in pairs. Experimental methods, not a human regimen.
Protocol source ↗ · Original journal PDF, p.60
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Phagocytic index: GHK plus Dalargin | 71.3 ± 5.1% versus 30.8 ± 3.1% in fracture controls | Uninjured control 70.7 ± 7.0%; n=8/group; M±m as printed · Day 10 · p<0.05 versus fracture control; Table 1 marks *2 |
| Phagocytosis activation index: GHK plus Dalargin | 2.4 ± 0.3 versus 0.4 ± 0.03 in fracture controls | Uninjured control 2.7 ± 0.2; GHK alone 1.2 ± 0.1; Dalargin alone 1.3 ± 0.1 · Day 10 · p<0.05 versus fracture control; pairwise superiority to single peptides not established by table symbols |
| Oxygen-dependent reserve: GHK alone | No significant increase versus fracture controls; remained below the uninjured reference | Figure 5 group 2 has no fracture-control significance star; no exact bar values digitized · Day 10 · Figure marker indicates p<0.05 versus uninjured animals |
| Oxygen-dependent reserve: GHK plus Dalargin | Increased versus fracture controls; not marked different from the uninjured reference | Figure 5 group 5; this does not establish equivalence to healthy animals · Day 10 · p<0.05 versus fracture control; exact plotted values not extracted |
| GHK plus Thymogen: phagocytic index | 75.3 ± 5.9% versus 30.8 ± 3.1% in fracture controls | This combination also improved uptake; its oxygen-dependent reserve did not show the same restoration pattern as GHK plus Dalargin · Day 10 · p<0.05 versus fracture control; Table 1 |
| Bone repair | More advanced callus remodeling described with GHK combinations; fracture line described as barely visible | Qualitative histology/radiography, not a quantified union-time or strength endpoint · Day 10 |
| Safety and clinical outcomes | No formal adverse-event series, infection-rate reduction or human treatment outcome reported | |
| Assay group sizes | Table 1 and Figure 5 report n=8/group; histology sample flow not separately established |
Table 1: all reported neutrophil phagocytosis results
| Group | Phagocytic index (%) | Phagocytic number | Phagocytosis activation index |
|---|---|---|---|
| Uninjured saline control | 70.7 ± 7.0 | 4.0 ± 0.3 | 2.7 ± 0.2 |
| Fracture + saline | 30.8 ± 3.1 *1 | 1.3 ± 0.1 *1 | 0.4 ± 0.03 *1 |
| Fracture + GHK | 40.7 ± 3.2 *1,2 | 2.7 ± 0.2 *1,2 | 1.2 ± 0.1 *1,2 |
| Fracture + Dalargin | 40.5 ± 3.0 *1,2 | 2.7 ± 0.2 *1,2 | 1.3 ± 0.1 *1,2 |
| Fracture + Thymogen | 53.2 ± 4.1 *1,2 | 2.8 ± 0.2 *1,2 | 1.7 ± 0.1 *1,2 |
| Fracture + GHK/Dalargin | 71.3 ± 5.1 *2 | 3.9 ± 0.3 *2 | 2.4 ± 0.3 *2 |
| Fracture + GHK/Thymogen | 75.3 ± 5.9 *2 | 4.0 ± 0.3 *2 | 2.6 ± 0.2 *2 |
| Fracture + Thymogen/Dalargin | 54.6 ± 5.1 *1,2 | 2.8 ± 0.2 *1,2 | 1.8 ± 0.1 *1,2 |
Original M±m notation; n=8/group, day 10. *1: p<0.05 versus uninjured animals; *2: p<0.05 versus fracture/saline control. Marks retain the original comparison groups. Missing *1 is not proof of equivalence, and these are not monotherapy-versus-combination tests.
This is an original animal study, not a clinical review. Neutrophil uptake and oxygen-dependent reserve are surrogate assays; bone outcomes are descriptive. The claimed synergy lacks a formal interaction test. The 2021 local-delivery study and the 2011 systemic patent belong to a related research program; independent replication or shared animals cannot be established from the available reports.
Source for these results ↗ · Reviewed 2026-11-07
- Population / setting
- Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified
- Source reviewed
- Original PDF recovered through CyberLeninka and checked against publisher-deposited Crossref metadata and the Russian Central Scientific Medical Library abstract. Selected methods, results, Table 1 and Figure 5 reviewed; no independent experimental audit. Received 25 September and accepted 20 December 2021; exact publication day not established.
Study limitations
- Small animal groups; randomization, blinded assessment, power calculation and complete participant flow are not described.
- The numerical endpoints are neutrophil assays, not fracture-union time, mechanical bone strength or clinical infection rates.
- Table significance symbols compare uninjured or fracture controls; they do not establish equivalence to healthy animals or a formal combination-interaction effect.
- Local intraosseous administration differs from the systemic 2011 patent experiment. Shared authors and related models do not establish independent replication; cohort overlap is unresolved.
- The peptide tested was unbound GHK, not GHK-Cu. Pairwise combinations used two peptides per group. The study had no three-peptide cocktail.
Reviewed 2026-11-07.
Randomized study in people · 2017
[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].
Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.
Insulin change · −22.4% versus −6.5% · Dalargin + standard care versus standard care · 3 months · p<0.001 for Dalargin changes; p<0.05 for standard-care changes
Study notes and original source
[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE].
Dontsov AV · Klinicheskaia meditsina
Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.
Results and tables
Reported findings and study design
Dalargin added to standard care was associated with larger changes in inflammatory and metabolic blood markers than standard care alone. Clinical cardiovascular events were not the reported endpoint.
123 coronary-heart-disease patients with metabolic syndrome randomized to standard care (63) or adjunctive Dalargin (60); 84 additional CHD patients without metabolic syndrome formed a separate comparison group.
Population or model 123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome
Dose, route and schedule
2 mg/day for ten days, with three courses during three months; route not specified in the indexed abstract.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Insulin change | −22.4% versus −6.5% | Dalargin + standard care versus standard care · 3 months · p<0.001 for Dalargin changes; p<0.05 for standard-care changes |
| TNF-α change | −55% versus −9.4% | Same randomized treatment groups · 3 months |
| IL-6 change | −56.3% versus −6.1% | Same groups · 3 months |
| Triglyceride change | −27.2% versus −17.4% | Same groups · 3 months |
| HDL cholesterol change | +17.4% versus +10.3% | Same groups · 3 months |
| Other Dalargin-arm changes | β-endorphin +32.6%; leptin −36.1%; cortisol −23.9%; LDL cholesterol −14% | Within-arm changes; not placebo-adjusted effects · 3 months · p<0.001 reported |
| Studied schedule | 2 mg/day for 10 days; 3 courses across 3 months | Reported study regimen |
Percentages are within-group changes. The abstract does not provide the interaction test, event rates or a cardiovascular risk reduction.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 123 patients with coronary heart disease and metabolic syndrome, randomized 63/60; an additional 84-patient comparison group without metabolic syndrome
- Source reviewed
- Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.
Study limitations
- Biomarker outcomes do not establish fewer cardiovascular events. Blinding and allocation concealment are not described in the abstract.
- Abstract only. Full methods, sample-size details and adverse-event tables were outside the review.
Reviewed 2026-11-01.
Research record · 2026
Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery
The phase III registry lists the randomized placebo-controlled trial as completed on 10 September 2026. No results are posted as of 11 October. The primary outcome is a seven-day composite of major postoperative complications.
Study notes and original source
Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery
· Clinical trial registry; results not posted
Format: Registry record · Reviewed: Registry fields checked
Botkin Hospital · ClinicalTrials.gov NCT07404358; updated 23 September 2026
The phase III registry lists the randomized placebo-controlled trial as completed on 10 September 2026. No results are posted as of 11 October. The primary outcome is a seven-day composite of major postoperative complications.
- Population / setting
- 200 participants; registry reports actual enrollment
- Source reviewed
- ClinicalTrials.gov API checked: status, enrollment, intervention, outcomes and absence of results.
Study limitations
- Completed status is not evidence of efficacy. The proposed reduction from 35% to 20% was a sample-size assumption, not an observed result.
- Registration was first posted in February 2026, after the May 2025 study start. Registry information is sponsor-reported.
Reviewed 2026-10-11.
Animal research · 2026
Opioid receptor agonist dalargin prevents stress-induced cardiac injury and improves myocardial pump function
In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.
Study notes and original source
Opioid receptor agonist dalargin prevents stress-induced cardiac injury and improves myocardial pump function
B. K. Kurbatov, M. Kilin, A. O. Venichenko, A. A. Boshchenko, S. V. Gusakova, L. N. Maslov · Bulletin of Experimental Biology and Medicine. 2026;182(8):129–133.
In female rats under 24-hour stress, Dalargin lowered serum CK-MB by 27% versus stressed controls. Partial pump-function recovery was reported without a numerical treated-group estimate; the model itself doubled end-systolic volume and lowered ejection fraction 27%.
Results and tables
Reported findings and study design
Reported findings
Dalargin reduced the serum CK-MB injury marker by 27% versus stressed controls; partial improvement in cardiac pump function was described.
Female Wistar rats under 24-hour immobilization stress; Dalargin versus stressed controls. Group sizes, precision estimates and p-values not supplied by the publisher abstract.
Population or model Female Wistar rats exposed to 24-hour immobilization
Dose, route and schedule
0.125 mg/kg intraperitoneally, 30 minutes before immobilization and 8 and 16 hours after its onset. Experimental animal regimen, not a human dose.
Protocol source ↗ · Publisher bilingual abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cardiac injury marker CK-MB | 27% lower with Dalargin than stressed controls | Animal biomarker comparison, not a clinical event reduction · 24-hour stress model · No p-value or confidence interval supplied in the abstract |
| Pump-function response to Dalargin | Partial reversal reported; numerical treated-versus-stress functional estimates not provided | |
| Stress model changes, not Dalargin effects | End-systolic volume doubled and left-ventricular ejection fraction fell 27% | Stress versus unstressed baseline/control; these figures must not be presented as treatment improvements |
| Reported animal protocol | 0.125 mg/kg intraperitoneally, before and twice during the stress period | Experimental regimen; not clinical administration advice |
Preclinical stress-injury model. No evidence here for human stress cardiomyopathy treatment or reduced cardiovascular events.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Female Wistar rats exposed to 24-hour immobilization
- Source reviewed
- Original publisher Russian and English abstracts; treatment effects separated from stress-model changes. Group sizes, uncertainty and full methods not verified.
Study limitations
- Animal stress model; this does not establish cardioprotection in people.
- Sample size, masking and full statistical methods require the complete paper.
Reviewed 2026-11-06.
Animal research · 2014
GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results
After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.
Study notes and original source
GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results
Unbound GHK, Dalargin and Thymogen given alone or in pairwise groups. · Conference proceedings paper
M. Yu. Smakhtin, G. M. Dubrovin, V. Yu. Cherdakov, Yu. V. Furman · Innovations in Medicine, Kursk State Medical University conference proceedings. 2014; pp. 256–258.
After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.
Results and tables
Reported findings and study design
The researchers fixed a closed right femoral fracture with an intramedullary wire. After ten days they measured neutrophil uptake of latex particles, counting 100 cells per smear.
Population or model Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.
Dose, route and schedule
Intraperitoneal treatment from the day of fracture for 10 days. Unbound GHK and Thymogen at 0.5 µg/kg each and Dalargin at 1.2 µg/kg, alone or in pairs. Fracture controls received an equivalent volume of saline.
Protocol source ↗ · Original proceedings paper, methods and Table 1.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Neutrophil phagocytic index | 69.17 ± 3.70% with GHK + Dalargin and 72.17 ± 5.25% with GHK + Thymogen versus 31.67 ± 2.03% with fracture plus saline. | Day 10 · Both p<0.05 versus fracture plus saline |
| Phagocytic index with GHK alone | 41.80 ± 2.50% with GHK, versus 31.67 ± 2.03% with fracture plus saline and 67.01 ± 4.33% without fracture. | Table 1 marks p<0.05 versus both controls |
| Fracture radiographs | The authors describe a less visible fracture line in treated groups, particularly with combinations. | Descriptive assessment |
Day-10 neutrophil phagocytosis, Table 1
| Group | Phagocytic index (%) | Particles per phagocyte | Activation index |
|---|---|---|---|
| Uninjured control | 67.01 ± 4.33 | 3.82 ± 0.19 | 2.51 ± 0.12 |
| Fracture + saline | 31.67 ± 2.03 | 1.35 ± 0.05 | 0.43 ± 0.04 |
| GHK | 41.80 ± 2.50 | 2.64 ± 0.14 | 1.19 ± 0.03 |
| Dalargin | 43.50 ± 2.65 | 2.70 ± 0.15 | 1.17 ± 0.03 |
| Thymogen | 55.00 ± 2.22 | 2.67 ± 0.17 | 1.41 ± 0.04 |
| GHK + Dalargin | 69.17 ± 3.70 | 3.74 ± 0.25 | 2.35 ± 0.23 |
| GHK + Thymogen | 72.17 ± 5.25 | 3.79 ± 0.17 | 2.71 ± 0.19 |
| Thymogen + Dalargin | 60.00 ± 3.50 | 2.85 ± 0.19 | 1.71 ± 0.05 |
n=8 per group. Values are shown as M±m, as in the original. The group-specific significance flags are in the original table.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.
- Source reviewed
- Original proceedings paper, methods and Table 1.
Study limitations
- The 2021 Mal conference paper repeats treatment-group phagocytosis means and errors exactly. The two reports are treated as overlapping evidence. The separate 2021 journal paper used intraosseous delivery and reports different numbers.
- The paper describes radiographs qualitatively. The cellular assays do not establish fracture union, mechanical bone strength or clinical effects.
Reviewed 2026-11-16.
Animal research · 2021
GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report
GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.
Study notes and original source
GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report
Unbound GHK, Dalargin and Thymogen given alone or in pairs. · Conference proceedings paper
G. S. Mal, A. M. Smakhtina, M. Yu. Smakhtin, A. A. Chulanova, K. I. Sunyaikin · Belikov Readings, 9th International Scientific and Practical Conference proceedings. Pyatigorsk, 2021; pp. 230–237.
GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.
Results and tables
Reported findings and study design
At day 10 the investigators assessed neutrophil oxidative activity using spontaneous and stimulated nitroblue tetrazolium (NBT) reduction. Functional reserve was the ratio of stimulated to spontaneous NBT. They also measured uptake of latex particles.
Population or model The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.
Dose, route and schedule
Intraperitoneal treatment from the day of fracture for 10 days. Unbound GHK and Thymogen at 0.5 µg/kg each and Dalargin at 1.2 µg/kg, alone or in pairs. Fracture controls received an equivalent volume of saline.
Protocol source ↗ · Original proceedings paper, methods and Figures 1–2.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Stimulated NBT response in blood neutrophils | 2.9× with GHK + Dalargin, 1.75× with GHK + Thymogen and 1.74× with Thymogen + Dalargin. | Reported fold changes versus fracture control |
| Neutrophil functional reserve | 1.69× with GHK + Dalargin, 1.31× with GHK + Thymogen and 1.28× with Thymogen + Dalargin. | Versus fracture control. GHK + Dalargin approached the uninjured reference. · Day 10 |
| Oxygen-dependent measures with GHK alone | The authors reported no substantial effect. | Figure 1 and results text |
| Latex uptake | The GHK + Dalargin and GHK + Thymogen phagocytic indices were 69.17 ± 3.70% and 72.17 ± 5.25%, matching the 2014 results. |
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.
- Source reviewed
- Original proceedings paper, methods and Figures 1–2.
Study limitations
- The published phagocytosis values repeat the 2014 report. The 60 animals stated in the 2021 methods are treated as overlapping with the earlier report. The 2021 intraosseous journal paper is a separate source with different methods and results.
- A normal-range laboratory result alone cannot establish equivalence to uninjured animals. These experiments do not establish a combined clinical effect or reduced infection rates.
Reviewed 2026-11-16.
Lab research · 1999
Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.
[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM
Study notes and original source
Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov · British Journal of Pharmacology. 128(3):569–576
Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.
Results and tables
Reported findings and study design
Isolated animal tissues comparing Dalargin analogues at opioid-receptor assay sites.
Population or model Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| [L-Ala²] analogue | 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM | |
| [Met⁵] analogue | Naloxone KB 5.5 nM | |
| Dalarginethylamide | Naloxone KB 5.0 nM | |
| N-methyl-[L-Phe⁴]-dalarginamide | δ/μ ratio 0.00053; naloxone KB 2.6 nM | |
| [D-Phe⁴] amide analogues | Inactive in the reported assays |
Each potency/ratio belongs to a particular analogue; the KB figures concern naloxone antagonism, not a Dalargin human affinity or dose.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Animal-tissue bioassays, not a human efficacy or safety trial.
- Dalargin analogues are not interchangeable with the parent peptide.
Reviewed 2026-10-04.
Experiment described in a patent · 2008
Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1
The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.
Study notes and original source
Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1
· Russian patent RU2323019C1
The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.
Results and tables
Reported patent results
Reported findings
Hearing improved in some patients, while 43% had no reported treatment effect.
Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
Population or model Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hearing outcome | 22.3% complete restoration, 34.7% improvement, 43% unchanged | Reported proportions; no modern randomized comparison established · After the treatment course |
| Hearing thresholds | Average reductions reported in the 15–30 dB range | Within-cohort change across speech/high frequencies · p<0.05 reported |
| Tinnitus | 49 patients reported complete disappearance; 9 less intensity; 5 unchanged | 63/123 had tinnitus initially; percentages in the source use the whole cohort denominator |
| Comparison with prior methods | Complete restoration 22.3% versus 7.3% and 9.8%; no effect 43% versus 67% and 64% | Comparator cohort sizes and concurrent comparability are not established |
Combined procedures, heterogeneous injuries, unclear comparator allocation and inconsistent percentage totals prevent a reliable Dalargin-alone effect estimate.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Patent case material does not establish randomized allocation, blinding or Dalargin monotherapy efficacy.
- One narrative passage reverses the restoration/improvement percentages; the summary follows the results tables.
- Mixed middle- and inner-ear injuries and associated procedures limit attribution.
Reviewed 2026-11-06.
Animal research · 2000
Dalargin and liver function during acute hypoxia
The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.
Study notes and original source
Dalargin and liver function during acute hypoxia
V. Yu. Kalinin · Candidate dissertation, 2000; web transcription
The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.
- Population / setting
- Rats; pressure-chamber model reported as approximately 12,200 m
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Rat experiments do not establish human altitude protection or a seven-day clinical effect.
- Original scan and survival tables remain to be reconciled; numerical survival values are withheld.
- The early time point appears as 0.15 hours in the transcription; it is not safely interpretable as 15 minutes.
Reviewed 2026-10-04.
Animal research · 2011
Protective activity of Mildronate, Dalargin and Picamilon in experimental stress
The dissertation examines three separate pharmacological approaches to experimental stress, including behavior, gastric injury and nonspecific cellular immunity. The comparative program connects opioid-peptide research with Picamilon and Mildronate.
Study notes and original source
Protective activity of Mildronate, Dalargin and Picamilon in experimental stress
T. I. Frantsuzova · Candidate dissertation, Saransk, 2011; 129 pages
The dissertation examines three separate pharmacological approaches to experimental stress, including behavior, gastric injury and nonspecific cellular immunity. The comparative program connects opioid-peptide research with Picamilon and Mildronate.
- Population / setting
- Experimental animal stress models
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Selected transcription reviewed; full tables and statistical appraisal remain pending.
- Head-to-head comparison is not evidence of a three-drug combination or human stress treatment.
Reviewed 2026-10-04.
Animal research · 1999
Post-resuscitation hemostasis correction with Dalargin and Mildronate
The Russian State Library verifies a 1999 experimental dissertation abstract on Dalargin and Mildronate in post-resuscitation hemostasis. A linked digital abstract is listed; efficacy and synergy claims require original-table review.
Study notes and original source
Post-resuscitation hemostasis correction with Dalargin and Mildronate
F. I. Razgonov · Omsk, 1999; dissertation abstract, 25 pages
The Russian State Library verifies a 1999 experimental dissertation abstract on Dalargin and Mildronate in post-resuscitation hemostasis. A linked digital abstract is listed; efficacy and synergy claims require original-table review.
- Population / setting
- Experimental resuscitation research
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Catalog metadata establishes the document, not the effectiveness of treatment.
- Animal resuscitation experiments cannot be generalized to healthy-user combinations.
Reviewed 2026-10-04.
Comparison in people · 2023
Dalargin and oxidative stress in severe combined trauma: a prospective clinical study
Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.
Mortality · 8/38 (21.1%) versus 17/66 (25.8%) · p=0.6412; nonsignificant
Study notes and original source
Dalargin and oxidative stress in severe combined trauma: a prospective clinical study
V. V. Antonova, A. K. Evseev, I. V. Goroncharovskaya, A. Yu. Ryzhkov, O. A. Grebenchikov, A. K. Shabanov · Annals of Critical Care. 2023;(4):185–196
Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.
Results and tables
Reported findings and study design
Reported findings
ARDS and kidney injury were less frequent; mortality, infection and overall ICU stay did not differ significantly.
104 trauma patients: 38 Dalargin, 66 controls; allocation safeguards unverified.
Population or model 104 severe combined-trauma patients
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mortality | 8/38 (21.1%) versus 17/66 (25.8%) | p=0.6412; nonsignificant |
| ARDS | 2/38 (5.3%) versus 14/66 (21.2%) | p=0.0457 |
| Acute kidney injury | 1/38 (2.6%) versus 13/66 (19.7%) | p=0.0286 |
| Overall ICU stay | 12.5 [6.0–34.5] versus 15.0 [5.0–34.0] days | Median [IQR]; narrative prints 36.5 for the first upper quartile · p=0.8635; nonsignificant |
| ICU stay among survivors | 29.0 [12.0–36.0] versus 36.5 [21.8–54.0] days | Survivor subset; selection may bias comparison · p=0.0015 |
| Infection and antioxidant activity | Infections comparable; antioxidant activity remained below normal |
Dalargin versus standard care throughout. Unequal groups and unverified assignment prevent causal inference. No survival benefit established.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 104 severe combined-trauma patients
- Source reviewed
- Original publisher HTML, selected clinical outcomes and Table 2 checked. Overall and survivor-only ICU stay distinguished; narrative/table upper-quartile discrepancy retained.
Study limitations
- Unequal groups; randomized allocation and blinding not established in this appraisal.
- Biomarker changes do not prove improved survival; survivor-only length of stay requires caution.
Reviewed 2026-11-06.
Animal research · 2002
Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion
The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.
Study notes and original source
Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion
· Indexed original publication; PMID 12124638
The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.
Results and tables
Reported findings and study design
Coronary-reperfusion experiment: Dalargin or DADLE 0.1 mg/kg immediately before reperfusion.
Population or model Experimental myocardial reperfusion
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ventricular arrhythmias | Prevention reported | |
| μ-receptor blockade | Abolished the antiarrhythmic effect |
Numerical arrhythmia counts not supplied in the indexed abstract.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Experimental myocardial reperfusion
- Source reviewed
- Selected source text and metadata checked; full risk-of-bias review pending.
Study limitations
- Preclinical model; no human treatment benefit established.
- DADLE and Dalargin are distinct peptides.
Reviewed 2026-10-04.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗